Table 2.
Initial characteristics of patients (total n =32); data are n (%) or mean (SD).a
| Men n (%) | 15 (44) |
| Age (years) | 60.1 (12) |
| Ethnic origin | |
| European | 12 (36) |
| Maori | 7 (21) |
| Pacific Islander | 13 (39) |
| Asian | 1 (3) |
| Body-mass index (kg/m2) | 29.2 (6.7) |
| Smoking status m (%) | |
| Current smokers | 4 (12.1) |
| Ex-smokers | 14 (42.4) |
| Asthma n (%) | 7 (21.0) |
| Chronic rhinosinusitis n (%) | 12 (38) |
| Bronchiectasis severity (Bhalla index) | 37.41 (13.0) |
| Sinusitis severity (Lund–Mackay score) | 6.9 (5.2) |
| Pre-bronchodilation FEV1(%) | 66.1 (21.4) |
| Post-bronchodilation FEV1(L) | 69.9 (21.4) |
| Pre-bronchodilation FVC (L) | 77.5 (13.7) |
| Post-bronchodilation FVC (L) | 80.0 (12.4) |
| Dartmouth COOP charts score | 22.2 (5.4) |
| LCQ score | 15.0 (4.2) |
| SNOT-20 score | 26.3 (17.2) |
| Serum 25(OH)D (nmol/L) | 70.5 (35.3) |
| Serum cathelicidin (ng/ml) | 24.9 (21.9) |
| Lund–Kennedy score | 2.6 (2.1) |
| Sputum 25(OH)D (nmol/L) | 19.4 (20.7) |
| Sputum cathelicidin (ng/ml) | 1615.1 (3254.4) |
| Serum CRP (mg/L) | 4.8 (6.8) |
| Serum ESR (mm/hr) | 27.1 (18.6) |
| Neutrophil count (109/L) | 3.9 (1.4) |
FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; 25(OH)D: 25-hydroxyvitamin D; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; LCQ: Leicester Cough Questionnaire; SNOT-20: 20-Item Sino-Nasal Outcome Test.
aThe Dartmouth COOP charts, LCQ and chronic rhinosinusitis symptoms score (SNOT-20) were administered at treatment initiation. FEV1 and FVC, which were performed at the initial screening and at treatment initiation, are averaged.